Clinical Resources

School for Young Neurologists

In-Person

London, United Kingdom

Jul 16, 2026 - Jul 18, 2026

Foundational / Beginner

1086<p>The MDS-ES School for Young Neurologist is designed for young neurologists and early-career movement disorder specialists who wish to deepen their expertise in the field of movement disorders, with particular focus on clinical examination, diagnosis and treatment. The program offers a comprehensive overview of main movement disorders and of recent developments on genetics, digital health and treatment with device aided therapies. Teaching will be delivered by internationally known experts from specialized movement disorder centre.<strong></strong><strong></strong></p>Biomarkers, Biomarkers & Diagnostic Tools, Botulinum toxin, Clinical Trials, Deep brain stimulation, Dopaminergic medications, Focused Ultrasound, Gene Therapies, Genetics, Infusion therapy, Medications for motor complications, Medications for motor symptoms, Medications for non-motor symptoms, Neuroimaging, Neuropathology, Rating Scales, Therapies-Pharmacological, Therapies-Surgical12600.00https://education.movementdisorders.org/Detail/1086/MDS-ES-School-for-Young-Neurologistshttps://education.movementdisorders.org/Upload/ActivityImages/26ESSYN_202x108554660.pnghttps://education.movementdisorders.org/Upload/BannerImages/26ESSYN_734x404520523.jpg2026-07-16T00:00:002026-07-18T00:00:00London, United Kingdom<p><br></p><p><br></p>MDS Education<p><a href="https://d1t84l7yt030ad.cloudfront.net/FroalaFiles/Course%20Agenda%20MDS%20ES%20SYN%20London%20NO%20Faculty_11032026080456.pdf" rel="noopener noreferrer" target="_blank"><img src="https://s3-us-east-2.amazonaws.com/mds-lms/FroalaFiles/Course schedule_23012024043738.png" style="width: 125px; height: 125px;" class="fr-fic fr-dib"></a><a href="https://d1t84l7yt030ad.cloudfront.net/FroalaFiles/Course%20Agenda%20MDS%20ES%20SYN%20London%20NO%20Faculty_11032026080456.pdf" rel="noopener noreferrer" target="_blank"><strong>Course Schedule</strong><strong>&nbsp; &nbsp;&nbsp;</strong></a><strong>&nbsp; &nbsp;&nbsp;</strong><a href="https://d1t84l7yt030ad.cloudfront.net/FroalaFiles/Faculty%20Listing_11032026085243.pdf" rel="noopener noreferrer" target="_blank"><img src="https://s3-us-east-2.amazonaws.com/mds-lms/FroalaFiles/Faculty Details_23012024043924.png" style="width: 125px; height: 125px;" class="fr-fic fr-dib"></a><a href="https://d1t84l7yt030ad.cloudfront.net/FroalaFiles/Faculty%20Listing_11032026085243.pdf" rel="noopener noreferrer" target="_blank"><strong>Course Faculty</strong></a></p><p><br></p><p><em>Schedule as of March 11, 2026&nbsp;</em><br><strong><em><span style="color: rgb(175, 38, 38);">Course Application</span><span style="color: rgb(184, 49, 47);">&nbsp;Deadline:&nbsp;</span></em></strong><em><span style="color: rgb(184, 49, 47);">April&nbsp;</span></em><em><span style="color: rgb(184, 49, 47);">1, 2026</span></em></p><p><br></p><p><strong>REGISTRATION FEES</strong><br><strong>Members:</strong>&nbsp;$250 USD<br><strong>Non-Members*:</strong>&nbsp;$325 USD</p><p>*<em>Non-members wishing to apply for MDS Membership to receive the MDS Member rate for this course will need to apply for membership no later than 2 weeks in advance of the close of registration.</em></p><p><a href="https://s3-us-east-2.amazonaws.com/mds-lms/FroalaFiles/VISA%20STATEMENT%20CANCELLATION%20LANGUAGE_24012024041714.pdf">Click here to view the MDS Regional Course Cancellation Policy &amp; Visa Assistance Information</a></p><p><br><strong>SCHEDULE OVERVIEW</strong><br>Day 1: Thursday, July 16, 2026 from 8:00 - 19:00<br>Day 2: Friday, July 17, 2026 from 8:30 - 21:30</p><p>Day 3: Saturday, July 18, 2026 from 8:00 - 13:00<br><br><span style="background-color: null;"><strong>COURSE VENUE</strong></span></p><p>St George&rsquo;s University Hospital,&nbsp;</p><p>Blackshaw Road, SW17 0QT</p><p>London, United Kingdom</p><p><br></p><p><strong>LEARNING OBJECTIVES</strong></p><p>Upon completion of this activity, learners will be able to:</p><p>1. To perform a structured and comprehensive clinical evaluation of patients presenting with movement disorders.<br>2. To present and analyze movement disorder case histories using a structured and evidence-based approach.<br>3. To deliver accurate diagnoses in patients with common and straightforward movement disorder presentations.<br>4. To formulate and critically appraise differential diagnoses in patients with complex or atypical movement disorder presentations.<br>5. To develop, evaluate, and appropriately modify individualized management plans in accordance with current evidence and best clinical practice.</p><p><br></p><p><strong>INTENDED AUDIENCE</strong></p><p>This activity is designed for young neurologists and early-career movement disorder specialists who wish to deepen their expertise in the field of movement disorders</p>London, United Kingdom0/Courses/School-for-Young-Neurologists3.htmSchool for Young Neurologists2026-03-11T12:01:06.83700Foundational / BeginnerIn-PersonBiomarkers &amp; Diagnostic ToolsTherapies-PharmacologicalTherapies-Surgical

Journal CME 41.02: Polyelectromyography Under Propofol to Differentiate Functional from Idiopathic Dystonia: A Pilot Study

On Demand

60 Minutes

Experienced / Intermediate

1076<p>The Journal CME 41.02 article aims to investigate potential differences in muscle activity between ID and FD patients using polyelectromyography (PEMG) under anesthesia.</p>Biomarkers, Biomarkers & Diagnostic Tools, Dystonia, Functional Movement Disorders, Genetics, Hyperkinetic Movement Disorders, Neuroimaging, Neuropathology, Other Movement Disorders, Rating ScalesRoberto Eleopra, MD601.00https://education.movementdisorders.org/Detail/1076/Journal-CME-41-02:-Polyelectromyography-Under-Propofol-to-Differentiate-Functional-from-Idiopathic-Dystonia:-A-Pilot-Studyhttps://education.movementdisorders.org/Upload/ActivityImages/Journal-CME562837664663.jpg2026-02-19T00:00:002027-02-19T00:00:00<p><strong>ACCREDITATION STATEMENT</strong></p><p>This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Parkinson and Movement Disorder Society is accredited by the ACCME to provide continuing medical education for physicians.</p><p><br></p><p><strong>CREDIT DESIGNATION STATEMENT</strong></p><p>The International Parkinson and Movement Disorder Society designates this activity for a maximum of 1 <em>AMA PRA Category 1 Credits&trade;</em>. Physicians should only claim credit commensurate with the extent of their participation.</p><p><br></p><p><strong>FACULTY DISCLOSURE</strong></p><p>All individuals in control of content for this activity are required to disclose all financial relationships with ineligible companies (as defined by the ACCME) over the last 24 months. Disclosure information is available <a href="https://d1t84l7yt030ad.cloudfront.net/FroalaFiles/Journal%20CME%2041.02%20-%20Disclosures_16022026081618.pdf" rel="noopener noreferrer" target="_blank"><u>HERE</u></a>. All relevant financial relationships have been mitigated in advance of this program.</p><p><br></p><p><strong>METHOD OF PARTICIPATION</strong></p><p>Each module will take approximately one (1) hour to complete. Upon reading the article, participants will take a post-test and must receive a grade of 75% or higher to pass. Participants are allowed multiple attempts to complete the post-test. Once the post-test is passed, participants are required to complete the module evaluation.</p><p><br></p><p><strong>SATISFACTORY COMPLETION</strong></p><p>Participants must complete an evaluation for each session they attend to receive continuing medical education credit. Your chosen session(s) must be attended in their entirety. Partial credit for individual sessions is not available.</p><p><br></p><p><strong>CONTENT VALIDITY STATEMENT</strong></p><p>All recommendations involving clinical medicine in MDS activities are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the case of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendations conforms to the generally accepted standards of experimental design, data collection and analysis. Activities that promote recommendations, treatment or manners of practicing medicine not within the definition of CME or are knowing to have risks or dangers that outweigh the benefits or are knowing to be ineffective in the treatment of patients do not constitute valid CME.</p>MDS Education<p><strong>COURSE PURPOSE</strong></p><p>Journal CME highlights various articles covering relevant issues, developments and research topics in the area of movement disorders. Articles are selected from Movement Disorders, the official Journal of the International Parkinson and Movement Disorder Society.</p><p><br></p><p><strong>LEARNING OBJECTIVES</strong></p><p>Upon completion of this activity, learners will be able to:</p><p>1. Understand the diagnostic overlap between functional and idiopathic dystonia and the need for objective biomarkers</p><p>2. Evaluate the role of sedation-based PEMG findings in differentiating FD from ID</p><p>3. Assess the clinical utility and limitations of EMG patterns under anesthesia in the diagnostic workup of dystonia</p><p><br></p><p><strong>INTENDED AUDIENCE</strong></p><p>This activity is intended for clinicians, other health professionals, researchers, policy makers from throughout the world, both MDS members and non-members, who interact with patients living with Movement Disorders.</p><p><br></p><p><strong>HARDWARE AND SOFTWARE REQUIREMENTS</strong></p><p>1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.</p><p>2. Compatible with Windows PC and MAC (256 MB of RAM or higher).</p><p>3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher.</p><p>4. Adobe Flash Player 12.0 (or higher).</p><p>5. Adobe Reader to print certificate.</p>0/Courses/Journal-CME-41.02-Polyelectromyography-Under-Propofol-to-Differentiate-Functional-from-Idiopathic-Dystonia-A-Pilot-Study.htmJournal CME 41.02: Polyelectromyography Under Propofol to Differentiate Functional from Idiopathic Dystonia: A Pilot StudyJournal CME 41.022026-02-19T09:01:11.36000Experienced / IntermediateOn-DemandBiomarkers &amp; Diagnostic ToolsHyperkinetic Movement DisordersOther Movement Disorders

Genetic Counseling in Parkinson's Disease

On Demand

60 Minutes

Foundational / Beginner

1050Genetics has become an important clinical tool and can also identify people at risk for disease.&nbsp; This is an introductory module on genetic counseling and testing for Parkinson&rsquo;s disease and includes some of the most important aspects to consider.&nbsp;Biomarkers & Diagnostic Tools, Genetics, Parkinson Disease/Hypokinetic Movement Disorders, Parkinson's Disease (PD)Deborah Raymond, MS, CGC, Maya Rawal, MS, CGC, Rachel Saunders Pullman, MD, MPH , MS601.00https://education.movementdisorders.org/Detail/1050/Genetic-Counseling-in-Parkinson's-Diseasehttps://education.movementdisorders.org/Upload/ActivityImages/05INTERACT-45-001-Genetic-Counseling-202x108969975.jpg2026-02-16T00:00:002029-02-16T00:00:00<p><strong>ACCREDITATION STATEMENT</strong></p><p>This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Parkinson and Movement Disorder Society is accredited by the ACCME to provide continuing medical education for physicians.</p><p><br></p><p><strong>CREDIT DESIGNATION STATEMENT</strong></p><p>The International Parkinson and Movement Disorder Society designates this activity for a maximum of 1 <em>AMA PRA Category 1 Credits&trade;</em>. Physicians should only claim credit commensurate with the extent of their participation.</p><p><br></p><p><strong>FACULTY DISCLOSURE</strong></p><p>All individuals in control of content for this activity are required to disclose all financial relationships with ineligible companies (as defined by the ACCME) over the last 24 months. Disclosure information is available <a class="fr-file" href="https://d1t84l7yt030ad.cloudfront.net/FroalaFiles/Disclosures - Genetic Counseling in Parkinson's Disease _17122025113848.pdf" rel="noopener noreferrer" target="_blank">HERE.</a> All relevant financial relationships have been mitigated in advance of this program.</p><p><br></p><p><strong>SATISFACTORY COMPLETION</strong></p><p>Participants must complete an evaluation for each session they attend to receive continuing medical education credit. Your chosen session(s) must be attended in their entirety. Partial credit for individual sessions is not available.</p><p><br></p><p><strong>METHOD OF PARTICIPATION&nbsp;</strong></p><p>Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed in the Accreditation Statement, it is your responsibility to contact your licensing/certification board to determine course eligibility for your board requirement.</p><p><br></p><p><strong>CONTENT VALIDITY STATEMENT</strong></p><p>All recommendations involving clinical medicine in MDS activities are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the case of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendations conforms to the generally accepted standards of experimental design, data collection and analysis. Activities that promote recommendations, treatment or manners of practicing medicine not within the definition of CME or are knowing to have risks or dangers that outweigh the benefits or are knowing to be ineffective in the treatment of patients do not constitute valid CME.</p>MDS Education<p><span style="background-color: null;"><strong>FACULTY</strong></span></p><p>Deborah Raymond, MS, CGC - Mount Sinai Beth Israel Medical, New York, NY, United States</p><p>Maya Rawal, MS, CGC - Mount Sinai Beth Israel Medical, New York, NY, United States</p><p>Rachel Saunders-Pullman, MD, MPH, MS - Mount Sinai Beth Israel Medical, New York, NY, United States</p><p><br></p><p><strong>LEARNING OBJECTIVES</strong></p><p>Upon completion of this activity, learners will be able to:&nbsp;</p><p>1. Understand the principal components of genetic counseling for Parkinson&rsquo;s disease</p><p>2. Understand the most common genetic contributors to Parkinson&rsquo;s disease&nbsp;</p><p>3. Understand genetic testing types</p><p>4. Understand the meaning of test results and how genetic variants are interpreted</p><p><br></p><p><strong>INTENDED AUDIENCE</strong></p><p>This activity is intended for students, residents, primary care providers, internists, allied health, non-neurology specialists, and industry who have limited to no movement disorder experience.</p><p><br></p><p><strong>HARDWARE AND SOFTWARE REQUIREMENTS</strong></p><p>1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.</p><p>2. Compatible with Windows PC and MAC (256 MB of RAM or higher).</p><p>3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher.</p><p>4. Adobe Flash Player 12.0 (or higher).</p><p>5. Adobe Reader to print certificate.</p>0/Courses/Genetic-Counseling-in-Parkinsons-Disease.htmGenetic Counseling in Parkinson's Disease2026-02-16T15:01:04.61700Foundational / BeginnerOn-DemandBiomarkers &amp; Diagnostic ToolsParkinson Disease/Hypokinetic Movement Disorders

Journal CME 41.01: Cerebrospinal Fluid Proenkephalin Predicts Striatal Atrophy Decades before Clinical Motor Diagnosis in Huntington's Disease

On Demand

60 Minutes

Experienced / Intermediate

1074<p>The Journal CME 41.01 article aims to investigate cross-sectional and longitudinal associations between baseline cerebrospinal fluid (CSF) PENK concentration and regional brain atrophy, compared identified patterns with CSF neurofilament light (NfL), and evaluated PENK and NfL for discriminating between HD Integrated Staging System (HD-ISS) stage 0 versus 1 in a far-from-onset HD gene-expanded (HDGE) cohort.</p>Biomarkers, Biomarkers & Diagnostic Tools, Chorea/Huntingtons Disease (HD), Hyperkinetic Movement DisordersMena Farag, MBBS, MRCP601.00https://education.movementdisorders.org/Detail/1074/Journal-CME-41-01:-Cerebrospinal-Fluid-Proenkephalin-Predicts-Striatal-Atrophy-Decades-before-Clinical-Motor-Diagnosis-in-Huntington's-Diseasehttps://education.movementdisorders.org/Upload/ActivityImages/Journal-CME562837664663.jpg2026-02-11T00:00:002027-02-11T00:00:00<p><strong>ACCREDITATION STATEMENT</strong></p><p>This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Parkinson and Movement Disorder Society is accredited by the ACCME to provide continuing medical education for physicians.</p><p><br></p><p><strong>CREDIT DESIGNATION STATEMENT</strong></p><p>The International Parkinson and Movement Disorder Society designates this activity for a maximum of 1 <em>AMA PRA Category 1 Credits&trade;</em>. Physicians should only claim credit commensurate with the extent of their participation.</p><p><br></p><p><strong>FACULTY DISCLOSURE</strong></p><p>All individuals in control of content for this activity are required to disclose all financial relationships with ineligible companies (as defined by the ACCME) over the last 24 months. Disclosure information is available <a href="https://d1t84l7yt030ad.cloudfront.net/FroalaFiles/Journal%20CME%2041.01%20-%20Disclosures_06022026033938.pdf" rel="noopener noreferrer" target="_blank"><u>HERE</u></a>. All relevant financial relationships have been mitigated in advance of this program.</p><p><br></p><p><strong>METHOD OF PARTICIPATION</strong></p><p>Each module will take approximately one (1) hour to complete. Upon reading the article, participants will take a post-test and must receive a grade of 75% or higher to pass. Participants are allowed multiple attempts to complete the post-test. Once the post-test is passed, participants are required to complete the module evaluation.</p><p><br></p><p><strong>SATISFACTORY COMPLETION</strong></p><p>Participants must complete an evaluation for each session they attend to receive continuing medical education credit. Your chosen session(s) must be attended in their entirety. Partial credit for individual sessions is not available.</p><p><br></p><p><strong>CONTENT VALIDITY STATEMENT</strong></p><p>All recommendations involving clinical medicine in MDS activities are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the case of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendations conforms to the generally accepted standards of experimental design, data collection and analysis. Activities that promote recommendations, treatment or manners of practicing medicine not within the definition of CME or are knowing to have risks or dangers that outweigh the benefits or are knowing to be ineffective in the treatment of patients do not constitute valid CME.</p>MDS Education<p><strong>COURSE PURPOSE</strong></p><p>Journal CME highlights various articles covering relevant issues, developments and research topics in the area of movement disorders. Articles are selected from Movement Disorders, the official Journal of the International Parkinson and Movement Disorder Society.</p><p><br></p><p><strong>LEARNING OBJECTIVES</strong></p><p>Upon completion of this activity, learners will be able to:</p><p>1. Understand the biological rationale for CSF proenkephalin as a striatum-specific biomarker in Huntington&rsquo;s disease<br>2. Assess associations between baseline CSF PENK and longitudinal regional brain atrophy compared with neurofilament light<br>3. Evaluate the role of CSF PENK in distinguishing early HD-ISS stages and its potential value for clinical trial enrichment<br><br></p><p><strong>INTENDED AUDIENCE</strong></p><p>This activity is intended for clinicians, other health professionals, researchers, policy makers from throughout the world, both MDS members and non-members, who interact with patients living with Movement Disorders.</p><p><br></p><p><strong>HARDWARE AND SOFTWARE REQUIREMENTS</strong></p><p>1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.</p><p>2. Compatible with Windows PC and MAC (256 MB of RAM or higher).</p><p>3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher.</p><p>4. Adobe Flash Player 12.0 (or higher).</p><p>5. Adobe Reader to print certificate.</p>0/Courses/Journal-CME-41.01-Cerebrospinal-Fluid-Proenkephalin-Predicts-Striatal-Atrophy-Decades-before-Clinical-Motor-Diagnosis-in-Huntingtons-Disease.htmJournal CME 41.01: Cerebrospinal Fluid Proenkephalin Predicts Striatal Atrophy Decades before Clinical Motor Diagnosis in Huntington's DiseaseJournal CME 41.012026-02-11T12:01:11.93000Experienced / IntermediateOn-DemandBiomarkers &amp; Diagnostic ToolsHyperkinetic Movement Disorders